Acumen Pharmaceuticals, Inc. — Director's Dealing 2021

Jul 1, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Acumen Pharmaceuticals, Inc. (ABOS)
CIK: 0001576885
Period of Report: 2021-06-30

Reporting Person: RA CAPITAL MANAGEMENT, L.P. (Director, 10% Owner)
Reporting Person: RA Capital Healthcare Fund LP (Director, 10% Owner)
Reporting Person: RA Capital Nexus Fund II, L.P. (Director)
Reporting Person: Kolchinsky Peter (Director, 10% Owner)
Reporting Person: Shah Rajeev M. (Director, 10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock	$		Common Stock (6122557)		Indirect
Series B Preferred Stock	$		Common Stock (1184366)		Indirect
Series B Preferred Stock	$		Common Stock (588850)		Indirect

Footnotes

F1: Each share of Series B Preferred Stock will automatically convert into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. The Series B preferred Stock has no expiration date.

F2: Shares held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F4: Shares held directly by the Nexus Fund II.

F5: Shares held directly by the Account.